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Abstract
Background: Genetic studies for complex diseases have predominantly discovered
main effects at individual loci, but have not focused on genomic and environmental
contexts important for a phenotype. Gene Set Enrichment Analysis (GSEA) aims to
address this by identifying sets of genes or biological pathways contributing to a
phenotype, through gene-gene interactions or other mechanisms, which are not the
focus of conventional association methods.
Results: Approaches that utilize GSEA can now take input from array chips, either
gene-centric or genome-wide, but are highly sensitive to study design, SNP selection
and pruning strategies, SNP-to-gene mapping, and pathway definitions. Here, we
present lessons learned from our experience with GSEA of heart failure, a particularly
challenging phenotype due to its underlying heterogeneous etiology.
Conclusions: This case study shows that proper data handling is essential to avoid
false-positive results. Well-defined pipelines for quality control are needed to avoid
reporting spurious results using GSEA.
Keywords: Gene set enrichment analyses, Heart failure, Coronary artery disease
Introduction
Gene Set Enrichment Analysis (GSEA) is a statistical method to assess whether differences
in expression of gene sets between two phenotypes are statistically significant [1, 2]. It was
initially designed for analysis of mRNA expression values, obtained from the then recently
developed microarray technology [3], based on the observation that existing methods at
the time were not capable of separating the small difference in expression profiles between
two classes, and a grouping strategy was necessary. The original study [3] also developed
collections of gene sets, based on biological knowledge available at the time.
Since then, multiple additional methods and reference gene sets have been devel-
oped, in an attempt to tackle caveats that emerged with the increase in use of GSEA
and the new types of data, such as genome-wide association studies (GWAS) and ex-
ome sequencing. Among the current existing methods, Pathway Studio [4],
MAGENTA [5], PANTHER [6], EVA [7] and Ingenuity [8] are commonly used,
whereas the most common gene set definitions are Gene Ontology [9], KEGG [10, 11],
REACTOME [12, 13], BIOCARTA [14] and MSIGdb [15].
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Heart failure (HF) is a major medical problem of the Western world, carrying a high
morbidity, mortality and economic burden [16, 17]. The susceptibility to develop HF is
thought to be partially genetically based [18], but despite a tremendous increase in
knowledge regarding etiology and risk factors for HF, still relatively little is known
about genetic factors related to HF incidence. Until now, genetic causes of HF have
mainly been identified in rare cases of non-ischemic HF with monogenic inheritance
[19]. Genetic studies for complex diseases, such as HF, focus on main effects of single
loci using strict statistical thresholds for significance, and typically do not consider
more complicated biological, genomic, or environmental hypotheses and models in
their primary scans.
While genome-wide studies have succeeded in identifying a multitude of genetic vari-
ants affecting disease risk, for incident heart failure (HF) thus far only two SNPs have
been identified in different ethnicities [20], most likely due to the relatively small sam-
ple sizes of the efforts so far, and the fact that HF is a very heterogeneous phenotype.
Functional SNPs with small main effects may not replicate across studies due to
context-dependent effects, such as the selection criteria of each cohort. Novel alterna-
tive analysis approaches to GWAS data that focus on the combined effects of many
loci, each making a small contribution to overall disease susceptibility, such as GSEA,
may provide a solution for the aforementioned limitations. Based on evidence from
GSEA, SNPs may be selected for further studies even if the association of that SNP
with heart failure is sub-genome-wide significant. Discovery of loci that contribute sus-
ceptibility to complex diseases like HF through gene-by-gene or gene-by-environment
interactions may segregate main effects at the individual loci that are weak or even en-
tirely absent, motivating approaches like GSEA or pathway-based methods that detect
association at the biological systems level.
We hypothesize that multiple loci interact to contribute to development of HF. GSEA
can be used to summarize genome-wide and exome array data integrating biochemical
systems and gene function. With possible gene-gene interactions present in gene sets,
potentially novel pathophysiological pathways can emerge, underlying the development
of HF, which are missed by conventional methods.
Given the statistical approach of each method, the gene sets and the input each one
takes, outputs obtained for a given phenotype may differ widely between GSEA
methods, causing uncertainty on how to interpret the data and move research forward.
Our goal in this paper is not to review each method separately (refer to Elbers et al.
[21] for a broad comparison), but instead to offer general guidelines that can be applied
to every method of the GSEA class. To illustrate these methods, we use genome-wide
data from the CHARGE consortium [20], PREVEND [22, 23] and Go-DARTS [24]
reporting incident HF, and CARDIoGRAM [25] and C4D [26] for coronary artery dis-
ease (CAD).
Cohort descriptions
Discovery
We use in this paper as input the results of the GWAS meta-analysis on incident heart
failure performed by the CHARGE (Cohorts for Heart and Aging Research in Genomic
Epidemiology) consortium [20]. The analysis of the CHARGE - Heart Failure Working
Group, part of the CHARGE Consortium, included 4 prospective cohort studies: the
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Atherosclerosis Risk in Communities Study (ARIC), the Cardiovascular Health
Study (CHS), the Framingham Heart Study (FHS) and the Rotterdam Study (RS).
These studies included participants of European and African ancestry who were
free of HF at study baseline. Incident HF cases were identified during follow-up by
self-report, administrative data or periodic clinical in-study examinations. A total of
20,926 participants of European ancestry and 2895 participants of African ancestry
with available genome wide data were eligible. The average age at baseline ranged
from 53.3 to 72.6 years and 57% were women. In total 2526 (12.1%) incident HF
events were identified among those of European ancestry over an average of
11.5 years follow-up and 466 (16.1%) during 13.7 years of follow up among those
of African ancestry. The average age at the time of HF onset was 73.6 years and
52% of events occurred among women. In those with European and African ances-
try, 73% and 78%, respectively, had no history of myocardial infarction prior to the
diagnosis of heart failure.
Replication
Firstly, we conducted replication using incident heart failure cases from the Genetics of
Diabetes Audit and Research Study in Tayside Scotland (Go-DARTS) [24], a cohort
with European individuals with type 2 diabetes, which was genotyped using Illumina
ExomeChip. This chip gives us the advantage of having one-to-one SNP-to-gene
mapping, because protein-coding SNPs were included in this chip, and their map-
ping is known. Secondly, we conducted replication using heart failure cases and
GWAS data of the Prevention of REnal and Vascular ENdstage Disease (PREVEND)
Study (n = 3,418, non-diabetics), a Dutch ongoing prospective study investigating the
natural course of increased levels of urinary albumin excretion and its relation to
renal and cardiovascular disease [22, 23].
All studies in CHARGE, Go-DARTS and PREVEND received institutional review
board approval, and all participants provided written informed consent for the use of
their DNA for research.
Initial pathway results
We analyzed the CHARGE [20] meta-analysis results for HF with EVA [7] using
MSIGdb [15]. We defined P < 0.05 as the threshold for significance, calculated via en-
richment tests counting the number of SNPs below this threshold as compared to the
total of SNPs mapped to each gene, in the first step. We mapped SNPs to genes using
BEDtools [27], dbSNP142 and the RefSeq gene reference, both datasets downloaded
from the UCSC Genome Browser [28], using a 500 kb window for mapping. We then
used the obtained gene p-values to calculate pathway p-values, by counting the number
of gene p-values below the significance threshold of 0.05 as a proportion of the number
of genes in each pathway.
We followed exactly the same procedure and phenotype (HF) for the other two
datasets (GoDARTS and PREVEND), with the exception of the SNP-to-gene map-
ping step for GoDARTS since all Exome chip SNPs are known to code specific
genes. Additional file 1: Table S1 presents p-values for all significant pathways in
the analysis of the CHARGE data and their p-values from the analyses of the other
two cohorts.
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Four pathways were significant for all three studies: KEGG_TYPE_I_DIABETES_
MELLITUS, KEGG_ALLOGRAFT_REJECTION, KEGG_GRAFT_VERSUS_HOST_
DISEASE and KEGG_ASTHMA. These pathways share a considerable amount of SNPs
(15 out of 30, 43, 36 and 41, respectively), the vast majority of which is related to the
MHC complex (Additional file 2: Figure S1). Permutation tests run in R [29] with
100000 simulations showed a low likelihood of these results arising by chance, with
P < 10−06 for Graft versus Host disease, P ~ 0.002 for Type 1 Diabetes and Asthma
and P ~ 0.007 for Allograft rejection (Additional file 1: Table S2).
Despite the multiple and convincing evidence in favor of the results, we explain
below why these are false positives, which is mainly as a consequence of data handling.
In the following sections we will explore strategies to avoid such false-positive findings
in GSEA.
Pre-processing the data
Every GSEA method is highly dependent on the input provided. As an example, while
PANTHER [6] accepts as input gene symbols without associated p-values, MAGENTA,
Ingenuity and EVA take as input SNP IDs with p-values, obtained, for instance, from
GWAS, and use this p-value information to calculate proportions of significant signals
according to predefined thresholds.
When providing SNPs and p-values to GSEA, it is important to check for the LD
structure of the data provided, since GWAS arrays and especially gene-centric arrays
have dense coverage in regions of particular interest, and lower coverage in other re-
gions of the genome. Such unbalance can lead to artificial enrichment of regions, in
case a densely covered region presents an LD block under the p-value threshold deter-
mined; the opposite can also happen, and a potentially important region may be lost
due to a non-significant LD block in the vicinity. A recent study by Sobota et al. [30]
concludes that an r [2] of 0.3 is a reasonable threshold to eliminate redundancy, and
our tests corroborate that recommendation, with the original 2,438,671 SNPs narrowed
down to 410,986, without losing any locus of the top SNP hits (P < 10−3).
SNP-to-gene mapping
Another crucial step is the SNP-to-gene mapping. Recent studies suggest that a 100 kb
window gives on average one mapping per SNP [31]. Using the same window of
100 kb, we obtained 2.6 mappings per SNP on average, with 1,801,727 SNPs mapped
4,762,714 times), at the cost of missing ~600 k SNPs, which are probably located in
gene deserts.
Larger windows can unveil promoter and enhancer mappings, which are commonly
within 500 kb regions of the SNP [32–34] (although enhancers can be found further
away [35]). Also, more complex regions, such as MHC, may have SNPs in LD separated
by over 3 M bases [36], and rare variant effects may be found up to 2.5 M bases away
from the tag SNP [37, 38].. We do not recommend large windows for SNP-to-gene
mapping, as the number of mappings becomes intractable: our tests showed an average
of 9 mappings per SNP with a 500 kb window, with 2,241,172 SNPs being mapped
20,159,139 times. For a 1 Mb window, 2,387,544 SNPs were mapped 34,793,184 times,
giving an average of 14.6 mappings per SNP, most of them likely to be false mappings
regarding LD structure (encompassing multiple unrelated genes, due to the mapping
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based only on distance). Such extensive mapping may lead to overplay of the effects of
a single SNP in multiple genes, and if it happens to be a highly significant gene, it could
drive the overrepresentation of a whole gene set [39]. These patterns remain even after
LD clumping (best proxy method implemented in Plink [40], independent of p-value),
with 301,509 SNPs mapped 830,835 times (average 2.8 mappings per SNP) for a 100 kb
window, and 367,854 SNPs mapped 3,542,909 times (average 9.6 mappings per SNP)
using a 500 kb window. A 100 kb window thus seems reasonable to obtain the most
manageable ratio of “true” mappings, under an assumption that the nearest genes are
most likely the ones affected by a variant (although it is arguably not always the case).
Gene sets
Efforts to represent collections of gene sets representing biological pathways have been
an active research topic for the past 20 years [9, 41, 42]. In general terms, each pathway
contains a set of genes that contribute to a certain metabolic process or biological func-
tion, obtained from a multitude of experiments. Each of these experiments and data-
bases has its own level of confidence, which may lead to spurious results if not taken
into account.
To explain this point, we describe an example. MSigdb [15] has collections of signa-
ture databases available that were composed in 2005, including KEGG [10]. The defin-
ition for Type I diabetes (T1D) from KEGG at MSigdb contains 44 genes, including 20
HLA genes. While it is striking that so many HLA-related genes play a role in develop-
ment of T1D at the same time, it is not surprising that inflammatory processes are in-
volved in the pathogenesis of this disease. However, KEGG updated its definition of the
T1D disease pathway with the most recent research findings, and it currently consists
of 22 genes, only three of which are HLA genes [43]. This new set is arguably more
precise, and is likely to lead to different results when used as definition of a GSEA, al-
though MSIGdb has not been updated since. Adriaens et al. [44] suggest that Reactome
should be taken as an initial database for analyses, because of its curation system,
which gives more reliable definitons. Other methods, such as Ingenuity [8], also have
curation systems, to improve the confidence on the results.
Recently, Frost et al. [45] addressed the problem of generality of pathways, i.e., mul-
tiple genes in the same region are assigned to a pathway due to the knowledge one of
these genes is involved in the process, but there is no certainty which. These re-
searchers used gene expression data to score how significant each gene of a pathway
definition actually is, and were able to narrow down pathways to represent more mean-
ingful biological processes. We believe this is a necessary step to help reduce false posi-
tive findings in GSEA.
Test case: CARDIoGRAM and C4D
In the GWAS field, the high number of false-positive findings of the early studies
[46–48] has led to a very stringent p-value significance threshold and a mandatory
replication step in independent samples [49, 50]. We believe that the GWAS proto-
col should be used to GSEA as well. In order to test our method, we decided to
use a well-established meta-analysis on CAD from the CARDIoGRAMplusC4D
consortium [51]. Coronary ARtery DIsease Genome wide Replication and Meta-
analysis (CARDIoGRAM) is a consortium of 14 cohorts with multiple recruitment
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criteria, assessing coronary artery disease (CAD) status of over 80,000 individuals
of European ancestry. The Coronary Artery Disease Genetics (C4D) is a similar
consortium, established to assess CAD status of over 30,000 patients from four dif-
ferent cohorts of European and south Asian ancestry. Results of independent meta-
analyses from CARDIoGRAM [25] and C4D [26] are available online, with GWAS
chip and imputed SNPs from CARDIoGRAM (~2.5 M SNPs) but only GWAS chip
results from C4D (~500 k SNPs). In order to level both datasets we performed im-
putation using DISTMIX [52] on C4D, and after imputation we had most of the
same SNPs in both datasets. After 1000Genomes-based clumping of an unrelated
phenotype, metabolic burden (methods described in Tragante et al. [53]) (r2 > =0.3),
both datasets had over 400,000 SNPs for pathway analysis. We used a 100 kb win-
dow around each SNP to map them to genes in the vicinity. Finally, we used a
combination of MSigdb gene sets C2 (curated gene sets) and C5 (Gene Ontology
gene sets), which include REACTOME, KEGG and Gene Ontology terms.
Using the full original CARDIoGRAM as the discovery set (given its bigger sample
size), we obtained 224 pathways with P < 0.05, 69 pathways with P < 0.01 and 13 path-
ways with P < =0.001. With C4D for replication, we obtained 21 of the 224 discovery
pathways under the P < 0.05 threshold, eight of those with P < 0.01 and two below
P < =0.001. With the clumped datasets, we obtained 250 pathways with P < 0.05, 68
pathways with P < 0.01 and 15 pathways with P < =0.001. Replication in C4D
reached 20 of 250 discovery pathways with P < 0.05, nine of those with P < 0.01 and three
with P < =0.001. Moreover, eight pathways are significant for both CARDIoGRAM and
C4D, original sets and clumped sets. The main pathway identified is Biocarta’s Acute
Myocardial Infarct pathway, which is an on-target result. Other pathways are related to
lipid and platelet metabolisms, which are also directly related to CAD and MI as risk
factors (Additional file 1: Table S3). One advantage of the clumped results over the ori-
ginal datasets is the convergence between gene p-values of both datasets. While for the
original datasets 30 out of 56 bona fide genes, (i.e., with genome-wide significant SNPs)
have either P < 0.05 or P > 0.05 on both datasets, for the clumped datasets, 38 out of
these 56 genes are convergent (Additional file 1: Table S4).
Rerunning the heart failure phenotype with complete preprocessing
Using CHARGE GWAS and imputed data (~2.5 M SNPs) as the discovery set (due
to the bigger sample size), we identified 54 pathways with P < 0.01, 3 of these with
P < =0.001 (Additional file 1: Table S5), which were the same three pathways that
were significantly associated after FDR correction (q = 0.05).
We used two independent cohorts to validate our findings: GoDARTS (~240 k exome
chip SNPs) and PREVEND (GWAS chip and imputed ~2.5 M SNPs). We used the fol-
lowing parameters for discovery and replication: clumped SNP lists with the lead signal
from an LD block of r2 > =0.3, a 100 kb window for mapping SNPs to genes, and
MSigdb gene sets C2 (curated gene sets) and C5 (Gene Ontology gene sets). Replication
in PREVEND resulted in 33 pathways with P < 0.01, 3 of these with P < 0.001
(Additional file 1: Table S6) and significant after FDR correction (q = 0.05). However,
there was no overlap between any of these pathways.
We then decided to increase our SNP-to-gene mapping window, to 500 kb, keeping
the other parameters the same. We then obtained 74 pathways with P < 0.01, 19 of
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those with P < 0.001 (Additional file 1: Table S7) and significant after FDR correction
(q = 0.05) with the CHARGE dataset, and 57 pathways with P < 0.01, 10 of those with
P < 0.001 (Additional file 1: Table S8) and significant after FDR correction (q = 0.05).
Two pathways overlapped between these two sets of results: NIKOLSKY_BREAST_
CANCER_16P13_AMPLICON, consisting of 120 genes, and NIKOLSKY_BREAST_
CANCER_8Q23_Q24_AMPLICON, consisting of 158 genes. We then investigated how
many of these genes have low p-values for both datasets. Surprisingly, none of the 120
genes of the first pathway were significant in both datasets, and only three out of the
158 genes of the second pathway had a P < 0.05 in the first pathway, which is lower
than expected by chance (binomial P = 0.03).
The possible advantage of the known SNP-to-gene mapping of the Exome Chip data
in their use in GoDARTS is undermined by the fact that there are few SNPs per gene
after clumping, leading to imprecise statistics per gene. Therefore, we could not make
use of the Exome Chip results.
Discussion
Gene set enrichment analysis is a strategy to bring insight into biological mechanisms that
lead to disease. Experience from years of GWAS analyses has shown that effect sizes of
genetic variants identified are small. Grouping these variants into biologically meaningful
pathways, such as is done by GSEA, seems to be a potential alternative to gain power and
identify true associations. A very detailed setup is necessary, however, to obtain reliable
and reproducible results. From our example, we have shown that false-positive results can
be found and even replicated without proper data handling. It is important to have well-
defined pipelines for quality control, in order to avoid publishing false-positives, re-
working and delay of scientific development. We provide in Fig. 1 a diagram of an ideal
GSE analysis, with all pre-processing steps we described in the paper.
The approach described proved successful for CAD/MI. Using CARDIoGRAM and
C4D, two big consortia that provide detailed meta-analysis results, we were able to
Fig. 1 Pipeline of a GSEA. Preprocessing is essential for all the input of the system
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identify significant pathways that replicated on both datasets, and results are directly
related to the phenotype. It is also worth noting that with the clumping, regions of high
coverage of non-significant SNPs are cleaned up, giving a better estimate of the contri-
bution of each gene in the phenotype. We exemplify this effect with the higher conver-
gence rate between CARDIoGRAM and C4D for genes mapped from the genome-wide
significant loci of the phenotype (38 out of 56, binomial P = 0.01).
Several factors may have played a role in the absence of positive results for the heart
failure phenotype after data QC. The phenotype definition is one of them. Given the
complexity of the heart failure syndrome with different phenotypes between distinct
ethnic cohorts and different etiologies, genome wide association studies on incident HF
can be hampered by heterogeneity. For particularly heterogeneous phenotypes such as
HF, large sample sizes are necessary to overcome the noise intrinsic to the data. Ideally,
a better phenotyping and subsetting of the individuals might lead to a more clear separ-
ation of the genotypes, and results would be clearer with the sample sizes of current
studies (~105 – 106 individuals). Of note, a similar GSEA setup in terms of SNP-to-
gene mapping and mapping window size, conducted by Ghosh et al. [31], in the domain
of coronary artery disease (CAD) (a less heterogeneous phenotype), with the aforemen-
tioned sample size (~105 – 106 individuals), succeeded in replicating pathways from
Reactome, at a P < 0.05 level. Their results led to new hypotheses on mechanisms of
CAD that make biological sense demonstrating that a more homogeneous phenotype
can lead to successful GSE analyses.
Furthermore, there is a predominance of immunological and cancer-related pathways
among the pathways available in MSigdb, coming from multiple papers on the subcat-
egory C2. Pathways with “cancer” as part of their names correspond to 9.4% of all path-
ways in this subcategory (446 out of 4725), and the terms “lymphoma”, “myeloma” and
“blastoma” bring an extra 268 results (5.7%). A more balanced list of reference pathways
may help identify biologically relevant processes for traits and diseases in other fields.
The SNP-to-gene mapping requires further improvement. In our tests, a window of
100 kb around the SNP position seems to provide the best ratio of mappings per SNP,
in terms of biologically plausible mappings (lower windows would reduce the SNPs
mapped up to over half of the input). We note, however, that this is not a final solution;
methods that integrate functional assays with LD blocks could help narrow down the
number of possible mappings, making the mapping more precise. Furthermore, there is
the need to avoid multiple mappings of a single significant SNP to genes, as it could
drive the overrepresentation of a whole gene set [39]. This mistake has led to retraction
of a manuscript, since the main result had been inflated by the same SNP being
mapped to eight genes in the same GO term [54]. This is a hypothesis to be investi-
gated in the future, by making use of the current deluge of data being produced for
functional analysis, such as ChIP-seq, RNA-seq, 4C-seq and eQTLs to provide a precise
SNP-to-gene mapping and limit noise. Moreover, new computational methods that esti-
mate the uncertainty of the potential causal, nearby gene(s) into the enrichment ana-
lysis could be very useful for appropriate significance assessment.
Conclusions
We believe that GSEA is particularly interesting, for example, in domains with high
heritability and low penetrance, such as glucose levels, since multiple mechanisms may
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be influencing the outcome. It may also be useful for phenotypes in which the known
genetic variants explain a low percentage of the phenotypic variance so far, such as
blood pressure, because the individual effect of the SNPs associated is small, and
grouping small effect SNPs can help in finding novel pathways. GSEA may also help
identify cross-ethnic analyses, since different functional SNPs from the same gene with-
out consistent effect across different populations may aggregate at the pathway level,
making pathways more likely to replicate than individual SNPs.
GSEA methods have been gaining momentum as part of the GWAS discovery
pipeline, and we believe that, with the appropriate setup and configuration, they will
help elucidate biological mechanisms underlying phenotypes and diseases.
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